期刊文献+

临床药师参与1例儿童活体肝移植术后华法林抗凝方案调整分析 被引量:4

Analysis of Warfarin Anticoagulant Treatment Adjustment Participated by Clinical Pharmacists for a Child after Living Donor Liver Transplantation
下载PDF
导出
摘要 临床药师参与1例儿童活体肝移植术后的抗凝治疗过程,深入分析影响患儿抗凝疗效的因素,结合患儿的病理生理特点,从药物选择、给药剂量、合并用药等方面提出个体化建议,临床医师采纳建议,患者经治疗后国际标准化比值(INR)控制在目标范围内,病情平稳出院。 Clinical pharmacists participated in the anticoagulant treatment process of a child after living donor liver transplantation,and the factors affecting the anticoagulant efficacy were thoroughly analyzed.According to the physiological and pathological characteristics of the patient,clinical pharmacists provided medical advice for clinicians in terms of drug choice,dosage and drug interactions.The clinicians adopted the recommendations,and the patient’s INR was within the target range after treatment and discharged with steady condition.
作者 林忠秋 刘滔滔 张宏亮 丘岳 陈依雨 Lin Zhongqiu;Liu Taotao;Zhang Hongliang;Qiu Yue;Chen Yiyu(Department of Pharmacy,the First Affiliated Hospital of Guangxi Medical University,Nanning 530021,China)
出处 《中国药师》 CAS 2020年第11期2199-2202,共4页 China Pharmacist
基金 广西壮族自治区卫生健康委员会自筹经费科研课题(编号:Z20200498)。
关键词 儿童 活体肝移植 抗凝 华法林 药学监护 Child Living donor liver transplantation Anticoagulant Warfarin Pharmaceutical monitoring
  • 相关文献

参考文献7

二级参考文献139

  • 1胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:162
  • 2Taube J,Halsall D,Baqlin T.Influence of cytochrome P2450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over anticoagulation in patients on long2term treatment.Blood,2000,96(5):1816-1819
  • 3Aithal G P,Day C P,Kesteven P J,et al.Association of polymorphisms in the cytochrome P450 CYP2C9 with wadarin dose requirement and risk of bleeding complications Lancet,1999,353(9154):717-719
  • 4Margaglione M,Colaizzo D,D'Andrea G,et al.Genetic modulation of oral anticoagulation with warfarin.Throm b Haem ost,2000,84(5):775-778
  • 5Yuan H Y,Chen J J,LceM T,et al.A novel functional VKORC1 promoter polymorphism is associated with inter-individual and interethnic differences in warfarin sensitivity.Hum M ol Genet,2005,14(13):1745-1751
  • 6Sconce E A,Daly A K,Khan T I,et al.APOE genotype makes a small contribution to warfarin dose requirements.Pharmacogenat Genomics,2006,16(8):609-611
  • 7Martin LA,Mehta SD.Diminished anticoagulant effects of warfarin with concomitant mercaptopurine therapy.Pharmaco therapy,2003,23(2):260-264
  • 8Jones CB,Fugate SE.Levofloxacin and warfarin interaction.Ann Pharmaco ther,2002,36(10):1554-1557
  • 9Goldstoin JA.Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.Br J Clin Pharmacol,2001,52(4):349-355
  • 10Chan TY.Interaction between warfarin and danshen(Salvia mitiorriza).Ann Pharmacother,2001,35(4):501-504

共引文献689

同被引文献48

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部